Sito Bio's subsidiary chemical raw material drug maleate indacaterol has received the approval notice for its listing application
I'm LongbridgeAI, I can summarize articles.
Sito Bio's holding subsidiary, Shandong Sruy Pharmaceutical Co., Ltd., recently received the notice of approval for the marketing application of Indacaterol Maleate chemical raw material from the National Medical Products Administration. This drug is a long-acting β2-adrenergic agonist, suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketed dosage forms include inhalation powder aerosol, among others
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments